Cyclerion Therapeutics, Inc. (CYCN) — Financial statements
Income statement, balance sheet, and cash flow for Cyclerion Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2↑3.7% | 2 | 0.00↓100.0% | 0.30↓91.1% | 3 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 6 | 0.00 | |
| Gross Profit | 2↑3.7% | 2 | 0.00↑100.0% | -5↓259.1% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.96↑235.3% | 0.29↓81.1% | 2↓74.7% | 6↓84.1% | 38 | |
| General & Administrative Expenses | 6↑14.0% | 5↓34.3% | 8↓36.8% | 13↓37.6% | 21 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 0.20↓50.0% | 0.40 | 0.00 | |
| SG&A Expenses | 6↑14.0% | 5↓35.9% | 8↓37.2% | 13↓35.7% | 21 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 3↑151.9% | -6↓2408.5% | 0.26 | |
| Operating Expenses | 7↑25.2% | 6↓56.5% | 13↓2.3% | 13↓77.3% | 59 | |
| Total Costs & Expenses | 7↑25.2% | 6↓56.5% | 13↓31.2% | 19↓67.8% | 59 | |
| Operating Results | ||||||
| Operating Income | -5↓37.1% | -4↑72.0% | -13↑30.1% | -19↑66.4% | -55 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 0.07↑0.0% | 0.07↓86.2% | 0.47 | |
| EBITDA | -5↓37.1% | -4↑62.1% | -10↑48.1% | -18↑65.7% | -54 | |
| EBIT | -5↓37.1% | -4↑62.4% | -10↑48.0% | -19↑65.9% | -54 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.13↓38.5% | 0.21↓41.9% | 0.36↑21.8% | 0.29↑1937.5% | -0.02 | |
| Interest Income | 0.13↓38.5% | 0.21↓41.9% | 0.36↑21.8% | 0.29 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -3 | 0.00↑100.0% | -0.88 | |
| Other Income / Expenses | 1↑153.1% | 0.57↑59.5% | 0.36↑21.8% | 0.29↓91.7% | 4 | |
| Income Before Tax | -4↓15.4% | -3↑75.7% | -13↑31.0% | -18↑64.7% | -52 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -4↓15.4% | -3↑75.7% | -13↑31.0% | -18↑64.7% | -52 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↓100.0% | 7↑128.4% | -26 | 0.00 | |
| Net Income | -4↓15.4% | -3↑41.9% | -5↑88.1% | -44↑14.7% | -52 | |
| Bottom-Line Net Income | -4↓15.4% | -3↑75.7% | -13↑31.0% | -18↑64.7% | -52 | |
| EPS (Basic) | -1.09↑9.9% | -1.21↑86.5% | -8.99↑55.4% | -20.15↑23.7% | -26.40 | |
| EPS (Diluted) | -1.09↑9.9% | -1.21↑86.5% | -8.99↑55.4% | -20.15↑23.7% | -26.40 | |
| Weighted Average Shares | 3↑28.1% | 3↑7.7% | 2↑7.6% | 2↑11.0% | 2 | |
| Weighted Average Diluted Shares | 3↑28.1% | 3↑7.7% | 2↑7.6% | 2↑11.0% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.